CIPLA stock news on Anadi Algo News

Wednesday, April 29, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
AnadiAlgoNews
सट्टा नहीं, सिस्टम
Stock Landing|50 matching stories

CIPLA Share Price, Latest News & Sentiment

Latest AI-analyzed news for CIPLA, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

CIPLA News Today

Large-cap stock hub

Global tech trends, especially AI, significantly influence investor sentiment. This news highlights the strong tailwinds for the AI sector.

Coverage
50
recent stories
Sources
9
distinct publishers
Bias Split
38 bullish / 8 bearish
4 neutral stories
Window
54d
recent coverage span
Saved Quote Snapshot

Cipla Limited

Last Updated
29 Apr 2026
Price
Rs 1,310.9
-0.48%
52W Range
Rs 1,165.7 - Rs 1,673
exchange snapshot
PE / VWAP
PE 23.41
VWAP Rs 1,310.19
Trend Read
mixed
EMA stack mixed
Business Context
Industry: Pharmaceuticals
Sector Trail: NIFTY 50
Listing Date: 1995-02-08
Market Structure
F&O Eligible: Yes
Indices: NIFTY 50, NIFTY500 SHARIAH, NIFTY QUALITY LOW-VOLATILITY 30
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 30 Sept 2024

Non-Consolidated results
What This Quarter Says

Cipla's latest financial report shows a revenue of Rs 4775.03 crore and a profit of Rs 1178.16 crore. This filing is on record. These numbers show how much money the company made and how much profit was left after expenses.

Revenue
Rs 4,775 cr
down 32.3% vs previous filing
Profit
Rs 1,178 cr
down 9.8% vs previous filing
EPS / Finance Cost
EPS 14.59
Finance cost Rs 3 cr
Filing Context
Filed 30 Oct 2024, 2:32 am
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 4,775 cr, down 32.3% vs previous filing.
  • Profit this quarter: Rs 1,178 cr, down 9.8% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 14.59.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

Top Themes

Pharmaceuticals18 mentionspharma14 mentionsInformation Technology4 mentionsAutomotive Components2 mentions

Related Stocks

SUNPHARMA15 linksDRL7 linksLUPIN4 linksNATCOPHARM2 linksADANIENT1 linksADANIPORTS1 links

Key People

Dilip Shanghvi3 mentionsUmang Vohra3 mentionsAnurag Singh1 mentionsOmar Abdullah1 mentions

CIPLA FAQ

Why is CIPLA in the news right now?

CIPLA has appeared across 50 recent stories from 9 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is CIPLA coverage bullish or bearish right now?

CIPLA coverage is currently leaning bullish, with 38 bullish, 8 bearish, and 4 neutral analyzed stories in the recent window.

Which themes are moving with CIPLA?

Recent CIPLA coverage is clustering around Pharmaceuticals and pharma. Related names showing up alongside CIPLA include SUNPHARMA, DRL, LUPIN.

How should I use this CIPLA news page?

Use this page as a coverage hub for CIPLA: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use CIPLA coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

Study Stock Execution

See a calmer workflow for converting CIPLA news into an actual plan.

Filter Related Names

Scanner-style filtering helps when one stock headline starts pulling attention across a cluster.

Read the Main Algo Guide

Use a broader framework if you want to move from one stock story to a repeatable process.

This is here if you want to go deeper, not as a push.Explore Anadi
Top Story|et_marketsabout 2 hours ago

Taiwan overtakes Canada to become 6th largest stock market as AI demand lifts TSMC m-cap to $1.8 trillion

Global tech trends, especially AI, significantly influence investor sentiment. This news highlights the strong tailwinds for the AI sector.

Bullish+20.170%
pharma
+20.1

Impact Score

Sectors Impacted

pharma
No direct trade setup for Indian stocks, but watch for indirect benefits to Indian IT services.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_companiesabout 10 hours ago

KKR invests Rs 1,750 cr in Baby Memorial Hospital

Significant PE investment highlights strong growth prospects in India's healthcare delivery sector.

buy
Bullish+57.695%
5 facts
Bullish for hospital chains; look for companies with strong balance sheets and expansion plans.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 10 hours ago

Oaktree Capital Accuses BJ’s of Reneging on Tariff Refund Trade

This is a US corporate legal matter, not relevant to Indian markets.

Bullish+12.695%
4 facts
No trade setup is implied or advised for Indian markets.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 10 hours ago

OxyContin maker Purdue Pharmas criminal sentence could be the last step before company dissolves

This is a US corporate legal matter, not relevant to Indian markets.

Bullish+12.695%
3 facts
No trade setup is implied or advised for Indian markets.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).

Latest CIPLA Stock Coverage

et_marketsabout 14 hours ago+53.9

KSDL clocks Rs 507 crore profit in FY26, revenue up at Rs 2,016 crore

5 factsFMCG
Positive sentiment for FMCG sector; look for listed companies with strong brand equity and distribution networks.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_marketsabout 16 hours ago+35.1

Deepak Builders' board approves 1:10 stock split

buy5 factspharma
Positive sentiment for the stock; watch for increased trading volumes post-split.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 16 hours ago+27.6

Monarch Networth raises ₹100 crore for PMS fund; reports 10.72% return since launch

5 facts
Monitor listed asset management companies for potential positive sentiment spillover.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 17 hours ago+35.1

Jashvik Capital expands medtech platform with Rivarp Medical investment

5 factspharma
Positive long-term bias for medical device manufacturers and distributors.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_companiesabout 19 hours ago+50.1

Institutional real estate investment falls 52% as domestic capital leads

5 factspharma
Mixed; positive for developers with strong domestic focus, but overall sector sentiment might be tempered by the institutional investment decline.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_companiesabout 19 hours ago+12.6

Vande Bharat to link Jammu and Srinagar capitals: Omar Abdullah hails ‘all-weather’ rail push

4 facts
Neutral for infrastructure stocks; await concrete project announcements.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 21 hours ago+44

Native logic: Urban Company bets on Diwali launch of AC-purifier hybrid to scale consumer durables business

5 factsConsumer DurablesE-commerce
Maintain a neutral to slightly cautious bias on established consumer durable stocks until the impact of new entrants like Urban Company becomes clearer; look for potential opportunities in ancillary industries.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_companiesabout 21 hours ago+44

Bain Capital-backed Dhoot Transmission acquires Multilink to boost electronics manufacturing

5 factsElectronics Manufacturing ServicesAutomotive Components
Maintain a bullish bias on Indian EMS stocks, focusing on companies with strong order books and diversified product portfolios, with a long-term investment horizon.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_companiesabout 23 hours ago+44

Bain Capital-backed Dhoot Transmission acquires Bengaluru-based MULTILINK

5 factsAutomotive ComponentsElectrical Equipment
Maintain a bullish bias on auto ancillary stocks with strong R&D and M&A activity in EV components, with a focus on companies demonstrating clear growth strategies in this segment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_marketsabout 23 hours ago+77.7

Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say

buy5 factsSUNPHARMAPharmaceuticals
Maintain a bullish bias on SUNPHARMA, looking for entry points on minor pullbacks, with strict risk management around key support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_marketsabout 23 hours ago+77.7

Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscape

buy5 factsSUNPHARMAPharmaceuticals
Maintain a bullish bias on SUNPHARMA, looking for consolidation or dips as potential entry points, with a focus on long-term growth prospects.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_marketsabout 24 hours ago+57.8

Cohance Lifesciences share price surges 37% in two days on appointment of new CEO

buy5 factsCIPLAPharmaceuticalsHealthcare
For Cohance Lifesciences, the immediate bias is bullish, but traders should consider the sharp rally and potential for short-term profit booking. A disciplined approach with stop-losses is crucial.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.
et_marketsabout 24 hours ago+71.8

Coherence Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surge

buy5 factsCOHANCECIPLApharmaceuticals
Long bias for Cohance Lifesciences; look for consolidation after the initial surge for potential entry points.|Quick check: COHANCE bullish bias (overbought), CIPLA bullish bias (overbought).
P R Sundar1 day ago+22.1

Pre Market Report 28-Apr-2026

4 factspharmafinancial_services
No specific trade setup; use for daily market preparation.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+44.6

Alvarez & Marsal looks to deepen India presence over the next year

5 factspharma
Bullish for financial services and sectors attracting foreign investment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+78.3

Dilip Shanghvi-led Sun Pharma's most expensive M&A deal signals fading allure of US generics business

buy5 factsSUNPHARMApharma
Strong bullish bias for Sun Pharma; consider long positions with a focus on integration success.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+74.6

Sun Pharma’s Organon buy took shape over three months of intense negotiations

buy5 factsSUNPHARMApharma
Bullish for Sun Pharma; focus on long-term growth from new therapeutic areas and geographies.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+67.1

How big is Organon’s biosimilar push for Sun Pharma?

buy5 factsSUNPHARMApharma
Bullish for Sun Pharma's long-term growth prospects in the biosimilar segment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_companies1 day ago+78.3

Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma deal

buy5 factsSUNPHARMApharma
Positive bias for large-cap pharma stocks with global ambitions; watch for further consolidation.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_companies1 day ago+52.1

IHH Healthcare seeks its investor Mitsui's help to set up talks with Daiichi in a ₹11,800 crore dispute

5 factspharma
Neutral for Indian pharma; no direct trading action based on this news for Indian-listed stocks.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_companies1 day ago+74.6

Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

buy5 factsSUNPHARMApharma
Positive bias for SUNPHARMA, but with an eye on execution risks. Consider long-term positions.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
et_economy1 day ago+63

India–New Zealand sign 'once-in-a-generation' FTA

buy5 factsDRLTextilesLeather
Long bias for Indian pharma stocks with strong export capabilities; maintain strict stop-losses given general market volatility.|Quick check: DRL neutral, CIPLA bullish bias (overbought).
et_economy1 day ago+63

India-New Zealand FTA to give major boost to exports: Experts

buy5 factsDRLCIPLAManufacturingPharmaceuticals
Consider a long bias on established Indian pharmaceutical companies with strong export capabilities, focusing on those with diverse product portfolios.|Quick check: DRL neutral, CIPLA bullish bias (overbought).
et_markets1 day ago+40.9

Monarch Networth Capital raises Rs 100 crore for its maiden PMS scheme

buy5 factsfinancials
Bullish for Monarch Networth Capital; potential for increased revenue and market share.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
livemint_markets2 days ago+76.6

Top Gainers & Losers on April 27: Sun Pharma, Varun Beverages, Suzlon Energy, Anant Raj among top gainers

buy5 factsSUNPHARMAVBLSUZLONInformation TechnologyPharmaceuticals
Consider a bullish bias for select pharma stocks with strong pipelines and export exposure; maintain strict stop-losses below recent support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), VBL bullish bias (overbought).
et_companies2 days ago+55.8

Sun Pharma: How a small Kolkata trader became a global buyout artist

sell5 factsSUNPHARMADRLCIPLAPharmaceuticals
Maintain a bullish bias on SUNPHARMA, but monitor for potential integration challenges and debt implications post-acquisition. Consider long positions with defined risk management.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
livemint_markets2 days ago+52.4

Sun Pharma acquires Organon: growth engine or debt trap?

hold5 factsSUNPHARMAPharmaceuticals
For SUNPHARMA, maintain a 'wait and watch' approach post-initial rally, focusing on integration news and debt management. Consider long positions only after clear signs of successful integration and debt reduction.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_markets2 days ago+44.9

Markets have moved on from geopolitics, broader rally underway: Anurag Singh

5 factsFinancial ServicesDiversified
While the article doesn't directly address pharma, a broader rally could see defensive sectors like pharma participate, especially if rupee weakness persists. Look for accumulation in quality pharma stocks with strong pipelines.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_markets2 days ago+58.8

Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang Vohra

hold5 factsCIPLAPharmaceuticalsHealthcare
For Cohance Lifesciences, maintain a bullish bias, but set clear stop-losses given the sharp initial move. Look for consolidation or further positive news for entry points.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.
MMB HDFC Bank2 days ago

[MMB HDF01] 790 touch kar gaya, abhi yeah thora up jaigaa, phir 3-4 session mai 770 tak wapis aayaigaa.

5 factsFinancials
No clear trade setup from this speculative comment; rely on established technical analysis and fundamental data for HDFC Bank.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
livemint_markets2 days ago+52.5

Sun Pharma share price rises 5% on acquisition of US-based Organon. Do you own?

hold5 factsSUNPHARMAPharmaceuticals
Maintain a bullish bias on large-cap pharma stocks with strong international exposure and a clear M&A strategy, while exercising risk discipline.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_markets2 days ago+3.7

Global Market Update: Market cap of South Korean-listed firms surpasses $4.08 trillion for 1st time

5 factsInformation Technology
Maintain a neutral to slightly bullish bias on select pharma stocks with strong product pipelines and favorable regulatory outcomes, using strict stop-losses.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_markets2 days ago+61.5

Sun Pharma shares in focus after firm announces $12-billion Organon acquisition

hold5 factsSUNPHARMAPharmaceuticals
Maintain a bullish bias on large-cap Indian pharma companies with strong M&A strategies, but always use stop-losses to manage event-driven risks.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_companies2 days ago+61.5

Sun Pharma to buy Organon in $11.75 billion all-cash deal

hold5 factsSUNPHARMApharma
Look for long opportunities in SUNPHARMA, anticipating positive re-rating due to strategic acquisition. Monitor integration risks.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_companies3 days ago+57.5

ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

sell5 factsSUNPHARMADRLLUPINPharmaceuticals
Maintain a bullish bias on large-cap Indian pharma stocks, particularly those with strong balance sheets and global ambitions, with a focus on M&A-driven growth. Risk discipline is crucial given the high debt component in such large deals.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
et_companies3 days ago-47.3

Telecom operators’ body urges govt to cut spectrum prices ahead of auction, cites weak 5G returns

5 factstelecom
Cautious to negative bias for telecom stocks until clarity on spectrum pricing emerges.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
et_markets4 days ago-54

Dalal Street Week Ahead: Nifty’s next big move hinges on support test; volatility set to stay high

hold5 factsNIFTYDRLNATCOPHARMEquity MarketPharmaceuticals
Consider a cautious, range-bound trading strategy for the Nifty, with a bearish bias if 23,800 is breached. Look for opportunities in defensive pharma stocks on dips, but with strict stop-losses.|Quick check: NIFTY neutral, DRL neutral.
et_markets5 days ago+46.9

Cipla among 6 stocks flashing bullish signals, hinting at a possible uptrend

buy5 factsCIPLAbroad_market
Consider long positions in Cipla and other identified stocks, with confirmation from volume and other indicators.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.
livemint_markets5 days ago+34

Stocks to watch: Infosys, Cyient, Adani Energy, RIL, LTIMindtree, among top shares in focus today

sell5 factsINFYCYIENTADANIENTInformation TechnologyOil & Gas
Consider a long bias in fundamentally strong pharma stocks, focusing on those with positive regulatory signals or robust product pipelines, with strict stop-losses.|Quick check: INFY bearish bias (-3.0% 1d), CYIENT neutral (-2.7% 1d).
et_companies6 days ago+56.6

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

hold5 factsCIPLAPharmaceuticals
Maintain a bullish bias on Cipla (CIPLA) with a focus on volume and price action post-announcement, setting clear stop-losses.|Quick check: CIPLA bullish bias (+0.5% 1d), SUNPHARMA bearish bias (+0.1% 1d).
ValuePickr7 days ago-37.8

Pharma || Hospitals || Diagnostics : Industry perspective

hold5 factsSUNPHARMACIPLApharma
Adopt a cautious to bearish stance on the pharma sector, favoring companies with strong R&D pipelines and diversified revenue streams.|Quick check: SUNPHARMA bearish bias (+0.0% 1d), CIPLA neutral (+0.4% 1d).
et_companies7 days ago-31.8

Alkem Labs CEO Vikas Gupta may exit company

buy5 factsALKEMCIPLAPharmaceuticals
Maintain a bearish bias on ALKEM in the short term, with a focus on price action around key support levels; consider a stop-loss above recent highs if taking a short position.|Quick check: ALKEM bullish bias (overbought), CIPLA neutral (+0.4% 1d).
livemint_markets19 days ago-53

US sales may drag pharma companies’ Q4, even as India holds up

hold5 factsCIPLADRLZYDUSLIFEPharmaceuticals
Maintain a cautious stance on export-oriented Indian pharma stocks; look for companies with stronger domestic growth or diversified international presence as potential outperformers.|Quick check: CIPLA neutral (+0.7% 1d), DRL neutral.
et_marketsabout 1 month ago-60.4

Cipla, GSPL among 6 stocks that hit 52-week lows; slip up to 24% in a month

sell5 factsCIPLAGSPLauto
Bearish bias for these specific stocks in the short term. Avoid catching falling knives unless there's a clear fundamental catalyst for reversal.|Quick check: CIPLA bearish bias (oversold), GSPL bearish bias (oversold).
et_marketsabout 2 months ago-60.9

Jefferies adds Wipro, Hyundai Motor India, Cipla to latest underperform list. Here’s why

sell5 factsWIPROCIPLAInformation TechnologyAutomobiles
For auto stocks, maintain a bearish bias, especially for those facing specific company-level challenges like Hyundai. Look for shorting opportunities or avoid fresh long positions, with strict stop-losses.|Quick check: WIPRO bearish bias (oversold), CIPLA bearish bias (-0.6% 1d).
MSNabout 2 months ago+1.1

Stocks in news today: Petronet LNG, JSW Infra, IOC, Adani Ports, Tata Motors CV, Cipla, Biocon - MSN

hold4 factsPETRONETJSWINFRAIOCbroad_market
No immediate trade setup from this stale news. Focus on current news flow and technicals for these stocks.|Quick check: PETRONET neutral (+4.0% 1d), JSWINFRA neutral (-0.0% 1d).